Epizyme Inc. (NASDAQ:EPZM) traded down 6.2% during trading on Friday . The stock traded as low as $8.12 and last traded at $8.16, with a volume of 322,837 shares traded. The stock had previously closed at $8.70.

Several equities research analysts have recently commented on the company. Leerink Swann reissued an “outperform” rating and set a $39.00 price target on shares of Epizyme in a research note on Tuesday, June 21st. Zacks Investment Research raised Epizyme from a “sell” rating to a “hold” rating in a research note on Wednesday, August 10th. JMP Securities reissued a “buy” rating and set a $28.00 price target on shares of Epizyme in a research note on Thursday, June 23rd. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Epizyme in a research note on Monday, May 9th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $26.00 price target on shares of Epizyme in a research note on Monday, June 20th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Epizyme currently has an average rating of “Buy” and a consensus price target of $23.11.

The company’s market cap is $472.92 million. The stock’s 50 day moving average price is $9.73 and its 200-day moving average price is $10.42.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.03. On average, equities research analysts forecast that Epizyme Inc. will post ($2.19) earnings per share for the current year.

In other Epizyme news, insider Robert A. Copeland sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $10.37, for a total value of $41,480.00. Following the sale, the insider now owns 35,538 shares in the company, valued at $368,529.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

An institutional investor recently raised its position in Epizyme stock. Jennison Associates LLC boosted its stake in shares of Epizyme Inc. (NASDAQ:EPZM) by 252.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 893,913 shares of the biopharmaceutical company’s stock after buying an additional 640,245 shares during the period. Jennison Associates LLC owned 2.14% of Epizyme worth $14,320,000 as of its most recent SEC filing.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.